Pyxis Oncology launches registered public offering with pre-funded and common warrants
Deal includes common stock or pre-funded warrants, each paired with a common warrant; warrants’ exercisability and expiry are tied to a charter amendment and disclosure milestones. Proceeds will fund MICVO development and working capital; joint bookrunners named, terms subject to market conditions.